OCEAN BIOMEDICAL INC (OCEA) Stock Price & Overview
NASDAQ:OCEA • US67644C1045
Current stock price
The current stock price of OCEA is 0.0205 USD. Today OCEA is down by -46.75%. In the past month the price decreased by -63.91%. In the past year, price decreased by -98.47%.
OCEA Key Statistics
- Market Cap
- 3.403M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.34
- Dividend Yield
- N/A
OCEA Stock Performance
OCEA Stock Chart
OCEA Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to OCEA. When comparing the yearly performance of all stocks, OCEA is a bad performer in the overall market: 99.84% of all stocks are doing better.
OCEA Earnings
OCEA Forecast & Estimates
OCEA Groups
Sector & Classification
OCEA Financial Highlights
Over the last trailing twelve months OCEA reported a non-GAAP Earnings per Share(EPS) of -0.34. The EPS increased by 90.24% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -1051% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
OCEA Ownership
OCEA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.01 | 375.559B | ||
| AMGN | AMGEN INC | 15.38 | 191.693B | ||
| GILD | GILEAD SCIENCES INC | 15.72 | 176.393B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.5 | 113.496B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.02 | 81.177B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 43.17 | 42.608B | ||
| INSM | INSMED INC | N/A | 34.4B | ||
| NTRA | NATERA INC | N/A | 28.771B | ||
| BIIB | BIOGEN INC | 10.76 | 25.993B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.14 | 25.192B | ||
| MRNA | MODERNA INC | N/A | 20.253B | ||
| INCY | INCYTE CORP | 12.54 | 19.296B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.068B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About OCEA
Company Profile
Ocean Biomedical, Inc. is a biopharmaceutical company. The company is headquartered in New York City, New York and currently employs 7 full-time employees. The company went IPO on 2021-09-15. The firm is focused on discovering and developing therapeutic products in oncology, fibrosis, infectious diseases, and inflammation. The firm helps to accelerates the development and commercialization of assets from research universities and medical centers. In oncology, it is engaged in developing a mono-specific and two bi-specific humanized monoclonal antibodies (mAb), product candidates targeting Chi3l1 for the treatment of non-small cell lung cancer (NSCLC), and of glioblastoma multiforme (GBM). The company offers three product candidates based on the novel target discoveries: a malaria vaccine candidate targeting either or both of PfSEA-1, and parasite antigen PfGARP, which is referred to as its ODA-570 candidate; a humanized mAb malaria therapeutic candidate targeting PfGARP, which is referred to as ODA-611 candidate, and a small molecule malaria therapeutic candidate targeting PfGARP, which is referred to as ODA-579 candidate.
Company Info
IPO: 2021-09-15
OCEAN BIOMEDICAL INC
515 Madison Ave Suite 8078
New York City NEW YORK US
Employees: 9
Phone: 16469082658
OCEAN BIOMEDICAL INC / OCEA FAQ
What does OCEAN BIOMEDICAL INC do?
Ocean Biomedical, Inc. is a biopharmaceutical company. The company is headquartered in New York City, New York and currently employs 7 full-time employees. The company went IPO on 2021-09-15. The firm is focused on discovering and developing therapeutic products in oncology, fibrosis, infectious diseases, and inflammation. The firm helps to accelerates the development and commercialization of assets from research universities and medical centers. In oncology, it is engaged in developing a mono-specific and two bi-specific humanized monoclonal antibodies (mAb), product candidates targeting Chi3l1 for the treatment of non-small cell lung cancer (NSCLC), and of glioblastoma multiforme (GBM). The company offers three product candidates based on the novel target discoveries: a malaria vaccine candidate targeting either or both of PfSEA-1, and parasite antigen PfGARP, which is referred to as its ODA-570 candidate; a humanized mAb malaria therapeutic candidate targeting PfGARP, which is referred to as ODA-611 candidate, and a small molecule malaria therapeutic candidate targeting PfGARP, which is referred to as ODA-579 candidate.
What is the stock price of OCEAN BIOMEDICAL INC today?
The current stock price of OCEA is 0.0205 USD. The price decreased by -46.75% in the last trading session.
Does OCEA stock pay dividends?
OCEA does not pay a dividend.
What is the ChartMill technical and fundamental rating of OCEA stock?
OCEA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
Where is OCEAN BIOMEDICAL INC (OCEA) stock traded?
OCEA stock is listed on the Nasdaq exchange.